are pleiotrophic growth factors that influence diverse processes such as skeletal development, hematopoiesis, and neurogenesis. They play crucial roles in diseases such as pulmonary arterial hypertension (PAH). In PAH, mutants of the BMP type II receptors (BMPR2) were detected, and their functions were impaired during BMP signaling. It is thought that expression levels of these receptors determine the fate of BMP signaling, with low levels of expression leading to decreased Smad activation in PAH. However, our studies demonstrate, for the first time, that the localization of receptors on the plasma membrane, in this case BMPR2, was misdirected. Three BMPR2 mutants, D485G, N519K, and R899X, which are known to be involved in PAH, were chosen as our model system. Our results show that all three BMPR2 mutants decreased BMP-dependent Smad phosphorylation and Smad signaling. Although the three mutants reached the cell membrane and their expression was lower than that of BMPR2, they formed smaller clusters and associated differently with membrane domains, such as caveolae and clathrin-coated pits. The disruption of these domains restored the Smad signaling of D485G and N519K to the level of wild-type BMPR2, showing that these mutants were trapped in the domains, rather than just expressed at a lower level on the surface. Therefore, new treatment options for PAH should also target receptor localization, rather than just expression level.
bone morphogenic protein receptors; mutants; colocalization; Smad signaling BONE MORPHOGENETIC PROTEINS (BMPs) are secreted signaling molecules that belong to the transforming growth factor-␤ (TGF-␤) superfamily. BMPs play an important role during embryonic development in chondrogenesis, osteogenesis, neurogenesis, and hematopoiesis (2, 7, 12) . Three type I and three type II receptors, all of which are serine/threonine kinases, have been identified. Among the three type II receptors, BMPR2, ActR-II, and ActR-IIB, BMPR2 is specific for BMPs, whereas ActR-II and ActR-IIB are shared by activins, myostatin, and BMPs. BMP receptors exist on the cell membrane as preformed hetero-or homooligomeric complexes. To activate the signaling pathways, BMPs bind to the receptors within distinct oligomeric structures (22) . After ligand binding to at least one, usually two, type I and two type II receptors, the type II receptor phosphorylates the type I receptor at the GS-box. The phosphorylated type I receptor then phosphorylates Smad1, Smad5, or Smad8. They in turn bind to Smad4, a common mediator, leading to nuclear translocation and regulation of specific genes (13, 15, 19, 23) . This is the moststudied BMP signaling pathway. Previous studies also indicate that BMP receptor distributions on the cell surface are highly flexible and dynamic. The change in their state of aggregation and their interaction with cell domains, such as caveolae, which are enriched with the protein caveolin, appear to be important for their signaling (24 -26) . The endocytosis of transmembrane receptors by clathrin-dependent and -independent pathways plays a major role in control of the receptor density on the cell surface (9, 10) . A recent study demonstrated that BMP receptor type II (BMPR2) is associated with clathrincoated pits (CCPs) and caveolar-like structures (11) . The CCPs are characterized by the presence of the three proteins: clathrin, dynamin, and the clathrin-associated adaptor protein 2 (AP-2).
Pulmonary arterial hypertension (PAH) is defined clinically by a sustained elevation of pulmonary arterial pressure (Ͼ25 mmHg at rest or Ͼ30 mmHg during exercise) without a demonstrable cause. The disease is most commonly sporadic but may also be associated with an autosomal-dominant mode of inheritance (familial PAH) in 6 -10% of patients. Both forms of the disease have an identical phenotype and exhibit preponderance in females of child-bearing age (6, 30, 32) .
Many recent studies present the cumulative results of a genome-wide search for the mechanism of this disease. It had been reported that heterozygous germline mutations in the gene encoding BMPR2 underlie the familial form of PAH (8, 16 -18) and a significant proportion of idiopathic or sporadic cases of PAH (18, 39) . More than 100 BMPR2 mutants have been recognized (17) . Three mutants, including the site mutations in the kinase domain (D485G) and in the cytoplasmic tail (N519K) and the truncating mutation in the cytoplasmic tail (R899X), were chosen as our model system. They are known to express on the cell surface but suppress the signaling activity or alter the known BMP signaling pathways (21, 31) . While it is generally thought that low expression of the receptors mediates decreases in Smad activation, we demonstrate here that the mutants are trapped within distinct membrane domains and that interference with the relocalization on the plasma membrane affects their activation state. We use image correlation spectroscopy (ICS) and image cross-correlation spectroscopy (ICCS) to analyze laser-scanning microscopy images to extract information regarding the clustering of receptors on cell membranes and the colocalization with cell membrane domains (5, 27, 34, 37, 38). We show that the aggregation and distribution on the cell membrane of BMPR2 and the three mutants differ significantly on human pulmonary artery smooth muscle cells (hPASMCs) and C2C12 cells. Their response is also different when cells are treated with an Eps15 (epidermal growth factor receptor pathway substrate clone 15, a newly identified component of CCPs that is required for receptormediated endocytosis) deletion mutant plasmid lacking the second and third EH domains, EH29 (1) and chlorpromazine (CPZ), to disrupt the CCPs or caveolin-1 small interfering RNA (siCav-1) and nystatin to disrupt caveolae. Our findings suggest that the dispersion and, probably, mislocalization of the mutant receptors contribute to the different BMP signaling observed in PAH. New therapeutics that can rescue the clustering and redistribute the receptors may provide potential treatments for PAH.
MATERIALS AND METHODS
Cell culture. C2C12 cells (CRL-1772, American Type Culture Collection, Manassas, VA) were grown in DMEM (Invitrogen) supplemented with 10% FBS (Invitrogen) at 37°C with 5% CO 2. Normal hPASMCs (PromoCell, Heidelberg, Germany) were cultured in smooth muscle cell growth medium (PromoCell) supplemented with Supplement Pack (0.5 ng/ml epidermal growth factor, 2 ng/ml basic fibroblast factor, 5 g/ml insulin, and 5% FCS; PromoCell) at 37°C with 5% CO 2. hPASMCs were used at passages 3-10. Construction of BMPR2 wild-type and mutant plasmids. BMPR2 wild-type and mutant plasmids were tagged with green fluorescent protein (GFP) and prepared as described previously (31) .
Transfection and labeling of hPASMCs and C2C12 cells. Before transfection, hPASMCs and C2C12 cells were subcultured on 35-mm glass-bottom petri dishes. When the cells reached ϳ90% confluency, they were serum-starved overnight and transiently transfected with 1.0 g of BMPR2-GFP, D485G-GFP, N519K-GFP, or R899X-GFP plasmids by the Lipofectamine LTX transfection reagent (Invitrogen, Burlington, ON, Canada). After 4 h, the culture medium was changed to fresh medium without serum and incubated for an additional 16 h. Before microscopic imaging, the cells were stimulated with 20 nM BMP2 (Biosource, Camarillo, CA) or not stimulated. The cells were observed under a microscope (C2C12 cells) or fixed and permeabilized by the methanol-acetone method (hPASMCs) (5) . Fixed hPASMCs were blocked by 3% BSA for 30 min and then incubated in the 10 g/ml antibody solutions: anti-caveolin-1␣ (clone 2234, catalog no. 610493, BD Biosciences), anti-caveolin-1␣/␤ (clone 2297, catalog no. 610407, BD Biosciences), and anti-AP-2-phycoerythrin (catalog no. sc-53163, Santa Cruz Biotechnology) for 1 h at room temperature. Finally, 20 g/ml Alexa 555-labeled anti-mouse IgG solution was used to label caveolin-1 at room temperature for 1 h. In every labeling step, cells were washed three times for 5 min with PBS buffer. Then the cells were mounted and observed under a microscope.
Luciferase gene reporter assay. C2C12 cells grown in a six-well tissue culture plate were serum-starved overnight before transfection. Then they were transfected with 0.5 g of pSBE, which is sensitive to the Smad signaling pathway (14) , 0.5 g of pRL-Luc reporter expression vectors, and 1.0 g of BMPR2/mutant constructs by the Lipofectamine LTX transfection reagent, unless otherwise mentioned. After 4 h, the culture medium was changed to fresh medium without serum, and the cells were stimulated for 18 h with 20 nM BMP2 or not stimulated. To disrupt the CCPs, 10 M CPZ (28, 36) was added to the cells for 18 h, with or without transfection with a mutant of Eps15-EH29 plasmid (1) during receptor transfection. To disrupt the caveolae, 10 g/ml nystatin (28, 29) was added to the cells for 18 h, with or without transfection of siCav-1 (Santa Cruz Biotechnology) during receptor transfection. Cells were lysed, and luciferase activity was determined using a dual-luciferase assay system (Promega, Madison, WI) according to the manufacturer's protocol.
Western blot analysis. Western blot analysis was carried out according to standard protocols. C2C12 cells grown in a six-well tissue culture plate were serum-starved overnight. Then they were transfected with 1.0 g of BMPR2 wild-type or mutant constructs by the Lipofectamine LTX transfection reagent. After 4 h, the medium was changed to fresh DMEM without serum. After 17 h, cells were stimulated with 20 nM BMP2 for 1 h or not stimulated. To disrupt the CCPs and caveolae, 50 M CPZ or 20 g/ml nystatin was added to the cells during the 1-h period of stimulation or nonstimulation. Cells were lysed for 1 h by the lysis buffer (10 mM Tris, 1 mM EDTA, 1% Triton, pH 7.4, and protease inhibitor cocktail). A normalized equal amount of cell lysate was injected into 10% SDS-polyacrylamide gel to separate the proteins. After transfer and blocking with 25 ) Smad8, 1:1,000 dilution; Cell Signaling] or antiSmad1/5/8 (1:200 dilution; Santa Cruz Biotechnology) for 1 h at room temperature. The horseradish peroxidase-conjugated secondary antibodies (1:1,000 dilution; Santa Cruz Biotechnology) also were incubated for 1 h at room temperature. The colorimetric 3,3=,5,5=-tetramethylbenzidine substrate (Promega) was used to detect the adsorbed antibodies. ImageJ software (http://rsb.info.nih.gov/nih-image/) was used to normalize band intensity.
Confocal microscopy. Images were collected using an LSM 510 confocal microscope equipped with an inverted Zeiss microscope. For fixed hPASMCs, the images were collected at room temperature; for live C2C12 cell imaging, cells were kept at 37°C in a temperaturecontrolled stage. Cells expressing the wild-type receptors and mutants were selected under mercury lamp illumination with a ϫ40 (1.3 numerical aperture) objective. An area of the cell, away from the nucleus, was enlarged and visualized using the confocal laser-scanning feature. For excitation, the 488-and 543-nm laser lines were used. Two scans were accumulated to produce a single image. One image was collected per cell, and 30 -40 images from different cells were collected per experiment. Three independent experiments (90 -120 cells) were repeated to ensure the reliability of the results. All the images were collected at identical instrument settings.
ICS and ICCS. ICS is based on analysis of spatial intensity fluctuations in images collected on a confocal laser-scanning microscope (5, 27, 34, 37, 38) . Autocorrelation functions, g(,), were calculated as described elsewhere (5, 27, 34, 37, 38) and fit to a two-dimensional Gaussian function
where and are the position lag coordinates (for the x-and y-axes, respectively) of the autocorrelation function, is the e Ϫ2 radius of the laser beam, and g(0,0) is the amplitude of the autocorrelation function upon extrapolation of and to zero; the offset, g 0, is introduced to account for the finite sample of the images, which can result in a decay of g(,) to a nonzero level at large lag coordinates. The zero-lag amplitude of the autocorrelation function, g(0,0), has been shown to be inversely proportional to the number of independently distributed particles in the observation area
A cluster density (CD) value, which is defined as the average number of independent fluorescent particles (clusters) per square micrometer of cell membrane, can be calculated as follows
The average intensity of an image, Ͻi(x,y)Ͼ, is proportional to the average number of fluorescent molecules in the area illuminated by the laser beam. Thus the degree of aggregation (DA), which is defined as the average number of molecules in the protein aggregate and is obtained by dividing the average total number of protein monomers, N m, by the average number of independent protein particles, N p, can be calculated
The constant c accounts for instrumental and experimental parameters (extinction coefficients, quantum yields and efficiency of collection of the confocal microscope). These parameters are constant for a given set of experimental conditions. ICCS is an extension of ICS, where a cross-correlation function is generated by calculation of the spatially coincident fluorescence intensity fluctuation in images collected from two different chromophores that are attached to two different protein types (5, 27, 34, 37, 38) . One protein type is labeled with a green probe and imaged to give the intensity map, i g(x,y); the second protein type is labeled with a red probe and imaged to give the intensity map ir(x,y). The normalized spatial cross-correlation function can be calculated as
The resulting cross-correlation function is fit to a two-dimensional Gaussian function as described above to give the amplitude of the cross-correlation function, g gr(0, 0). Thus we can define the CD of colocalized chromophores as
The fraction of each protein type associated with the other type can be calculated by examining the ratio of CD values
where F(g/r) represents the fraction of green-labeled protein clusters that contain red-labeled proteins and, correspondingly, F(r/g) represents the fraction of red-labeled protein clusters that contain greenlabeled proteins. ICCS provides the quantitative information about the extent of colocalization of two different proteins. The ICS and ICCS analysis was performed in the ImageJ program using available software from National Institutes of Health Image.
RESULTS

Overexpression of BMP receptor mutants (D485G, N519K, R899X) led to decreased BMP-dependent Smad phosphorylation and Smad signaling activity.
Three mutants, with site mutations in the kinase domain (D485G) and in the cytoplasmic tail (N519K) and truncating mutation in the cytoplasmic tail (R899X), were identified to localize to the plasma membrane of hPASMCs; however, Smad phosphorylation and Smad signaling are impaired in response to BMP2. Figure 1 illustrates the structure and mutation sites of the BMPR2 and the three mutants of interest. In this study, C2C12 cells were transfected with plasmids encoding BMPR2 and the mutants in combination with or without pSBE and pRL-Luc (normalization) for luciferase gene reporter assay and Western blot analysis.
The normalized band intensities of phosphorylated Smad1/ 5/8 relative to total Smad1/5/8 illustrate that all three mutants Decrease in clustering and expression of BMP receptor mutants compared with BMPR2 on the cell surface. hPASMCs were transfected with plasmids encoding BMPR2 or the BMPR2 mutants. At 24 h after transfection, confocal microscopic images were collected. As shown by the individual fluorescence spots in Fig. 2 , A-D, all the receptors reach the cell membrane. However, the pattern of expression is quite different between wild-type BMPR2 and the mutants. In Fig. 2 , A-D, typical confocal microscopic images at high magnification show the protein distribution on a selected region of a single cell for BMPR2, D485G, N519K, and R899X. BMPR2 is seen in particles on the surface as very bright fluorescence spots; the mutants are seen as fluorescence spots that appear much less bright. The typical autocorrelation functions of the images in Fig. 2 , A-D, are shown in Fig. 2 , E-H. For wild-type BMPR2, the autocorrelation function amplitude value is ϳ0.3, while those of the mutants are ϳ0.03, 10-fold less, in these examples. In ICS analysis, a smaller amplitude of the autocorrelation function corresponds to a greater average number of clusters and, therefore, a greater dispersion. Figure 3A shows the average intensity of the fluorescence signal for BMPR2 and the three mutants. The wild-type receptor is expressed at the highest level on the hPASMC surface, while the mutant receptors are expressed at less than half this level, even though the same amount of plasmid was transfected into the cells and the same experimental conditions were set during the microscopic observation and ICS analysis. A total of 90 -120 confocal microscopic images for each of the wild-type receptors and the mutants from three independent experiments were collected and analyzed by ICS. Two parameters that describe the distribution of receptors on the cell surface (CD), the average number of clusters per unit area, and DA, the average numbers of monomers in one cluster, were obtained from this analysis. Figure 3 , B and C, shows CD and DA values of BMPR2 and the three mutants. On the hPASMC membrane, wild-type BMPR2 forms large, aggregated clusters, as seen by the small CD value and large DA value. In contrast, D485G, N519K, and R899X are approximately equally highly dispersed on the cell surface, even though they are mutated at different locations and in different ways. CD values of the mutants are twice that of BMPR2, and DA values are five to six times smaller than that of BMPR2. It is possible that the distribution of the BMPR2 mutants may have reached the monomer level. It is evident that the receptors reach the cell membrane, but the three mutants are expressed at lower levels and are much less aggregated than wild-type BMPR2.
Upon stimulation with BMP2 (Fig. 3, A-C) , the intensity of fluorescence from BMPR2 and the three mutants is unaffected. This suggests that the number of receptor molecules that are expressed on the cell membrane remain the same with and without BMP2 stimulation. CD and DA values, however, are significantly affected by BMP2 stimulation. In all cases, the CD decreases and the DA increases as a result of exposure to BMP2, indicating that the receptors redistribute into fewer and larger clusters upon BMP2 stimulation. Wild-type BMPR2 is already present in highly aggregated clusters on the cell surface prior to stimulation by BMP2 and is further aggregated by ϳ12%. This confirms previous results, obtained with myctagged BMPR2 expressed on COS-7 cells, that showed BMPR2-myc redistribution into fewer, but larger, aggregates upon BMP2 stimulation (25) . The receptors of the three mutants, D485G, N519K, and R899X, also redistribute into fewer (20 -35%), but larger (35-50%), clusters (P Ͻ 0.05) following exposure to BMP2; however, in all cases, the number of clusters of the mutant receptors is still greater that that of the wild-type receptors by a factor of 2, and the clusters are still smaller than those of wild-type BMPR2 by a factor of ϳ4. Thus BMP2 stimulation fails to bring the mutants to the level of clustering seen in the wild-type receptors, even when the latter are not stimulated.
The three mutants of BMPR2, D485G, N519K, and R899X, represent three different types of mutations that have different effects on the BMP receptor signaling process (21, 31) . To determine whether BMP2 has a different effect on their distributions, using all the data available, we compared the relative change in the CD and DA upon stimulation for the three mutants. Upon BMP2 stimulation, the CD decreased by 23% for D485G, 30% for N519K, and 35% for R899X, while the DA increased by 39%, 52%, and 36%, respectively (P Ͻ 0.05). Fig. 3 , A-C, were calculated from 90 -120 cells in which the BMPR2 and mutants, on average, had different levels of expression. It is evident that the expression level varies from cell to cell in the same population, and it is possible that the image collection introduces a bias in sampling. We also noted that the CD of wild-type BMPR2 and the three mutants increased as the expression level increased, but DA remained the same (see Supplemental Fig. S2 ). To eliminate any possible effect of expression level on the receptors' distribution measurement, we selected ϳ40 cells with comparable expression levels, as measured by fluorescence intensity, of wild-type and mutant receptors and compared their distributions. Figure 3D confirms that, for these cells, the average intensity of the wild-type and Fig. 2 . Representative images and autocorrelation functions show expression of wild-type BMPR2 and mutants on human pulmonary artery smooth muscle cell (hPASMC) membrane. Plasmids encoding BMPR2-green fluorescent protein (GFP) and D485G-GFP, N519K-GFP, and R899X-GFP were transfected into hPASMCs by the Lipofectamine LRX method. After 24 h of transfection, cells were observed under confocal fluorescence microscopy. Areas distant from the nucleus on the cell surface were enlarged and captured. A-D: confocal images of BMPR2-GFP, D485G-GFP, N519K-GFP, and R899X-GFP, respectively, on hPASMC membrane. Scale bars, 2 m. E-H: typical autocorrelation functions of BMPR2-GFP, D485G-GFP, N519K-GFP, and R899X-GFP, respectively, obtained from image correlation spectroscopy (ICS) analysis.
BMPR2 and mutants show different states of aggregation, even at the same expression level. The results in
each mutant receptor with and without BMP2 stimulation is the same. The average CD and DA values with and without BMP2 stimulation for these cells shown in Fig. 3 , E and F, suggest results similar to those shown in Fig. 3 , A-C, for the complete data set. At the same expression level, wild-type BMPR2 still formed larger clusters on the cell surface than all three mutants. Stimulation by BMP2 led to significant increases in aggregation, but the mutants were always more dispersed than the unstimulated wild-type receptors. Additionally, aggregation of BMPR2 and mutants on live C2C12 cells at 37°C is similar to that on hPASMCs (see Supplemental Fig. S3 ).
Altered colocalization of BMPR2 mutants with membrane domains compared with BMPR2. Cell membrane domains, like caveolae and CCPs, play important roles in many cell functions. We have investigated the distributions of wild-type BMPR2 and the three mutants in these different cell domains. Fig. 3 . A-C: expression level of mutants was lower on the surface, and mutants localized in different clusters on the hPASMC membrane, as shown by cluster density (CD) and degree of aggregation (DA). A: corrected intensities of BMPR2-GFP and D485G-GFP, N519K-GFP, and R899X-GFP with and without BMP2 stimulation (ϩBMP2 and ϪBMP2, respectively). In the same experimental settings, expression of wild-type (wt) BMPR2 on the hPASMC surface was higher than that of the mutants. BMP2 stimulation did not affect expression of BMPR2 and mutants. B and C: CD and DA of BMPR2 and mutant receptors with and without BMP2 stimulation. Wild-type BMPR2 formed highly aggregated clusters on the cell surface, and mutant receptors were highly dispersed on the cell surface. After BMP2 stimulation, wild-type BMPR2 became somewhat aggregated, and the mutants were significantly aggregated but were still more dispersed than unstimulated BMPR2. D-F: results from ICS analysis of BMPR2 and mutants at the same expression level with and without BMP2 stimulation. Different aggregation/localization of BMPR2 and mutants receptors is independent of expression. About 40 cells with comparable expression levels, as measured by fluorescence intensity, of wild-type and mutant receptors were chosen from the cells analyzed in A-C. D: average intensities of BMPR2-GFP and D485G-GFP, N519K-GFP, and R899X-GFP with and without BMP2 stimulation. Level of expression was the same, and BMP2 stimulation did not change expression level of BMPR2 and mutants. E and F: CD and DA of BMPR2 and mutants with and without BMP2 stimulation. At the same expression level, wild-type BMPR2 still forms more highly aggregated clusters than the mutants on the cell membrane. Upon BMP2 stimulation, mutants aggregated significantly but were still more dispersed than unstimulated BMPR2.
a Significantly different from wild-type BMPR2 (ϪBMP2). b Significantly different from wild-type BMPR2 (ϩBMP2). c Significantly different from ϪBMP2 within group. P Ͻ 0.05 was considered statistically significant as determined by ANOVA followed by Tukey's test.
We transfected the BMPR2 and mutant plasmids fused with GFP into the hPASMCs, labeled the cells with antibodies against caveolin-1␣/␤, caveolin-1␣, and AP-2, and determined their colocalization using ICCS. Figure 4 , A-C, shows the overlay fluorescence images of wild-type BMPR2 with caveolin-1␣/␤, caveolin-1␣, and AP-2, and Fig. 4 , D-F, shows the fraction of colocalization of wild-type receptors and mutants with caveolin-1␣/␤, caveolin-1␣, and AP-2 obtained using ICCS.
The results in Fig. 4 show that the wild-type receptor and mutants colocalized to some extent with the cell domains enriched with caveolin-1␣ and -1␤ and in CCPs in the resting cells. Upon BMP2 stimulation, there was no significant change in the amount of the wild-type receptor colocalized with caveolin-1␣/␤, while that colocalized with caveolin-1␣ appears to increase slightly, indicating that some wild-type BMPR2 may have shifted from the region of caveolae enriched with caveolin-1␤ to the region enriched with caveolin-1␣, as previously observed (24, 26) . For the three mutants, colocalization with caveolin-1␣ was always equal to or greater than that with caveolin-1␣/␤, suggesting that none of the mutants were associated with caveolae enriched with caveolin-1␤. Correspondingly, the BMP2 stimulation did not lead to a shift from caveolin-1␤ to -1␣. Similarly, compared with the wildtype receptor, twice the amount of mutants colocalized with AP-2 in resting cells, and BMP2 stimulation did not change the distributions of wild-type receptors or mutants with AP-2. Because antibodies to caveolin-1␣/␤ and -1␣ bind to some of the same domains, the fractions need not add to 1. The total expression level of wild-type BMPR2 and mutants shows no correlation with the relative association with cell domains (see Supplemental Fig. S4) .
Site mutation mutants were trapped in cell domains. To investigate the potential mechanism whereby the mutants inhibit the BMP2-dependent Smad phosphorylation and Smad signaling, we used CPZ (28, 36) and a mutant of Eps15, EH29 (1), to disrupt the CCPs and nystatin (28, 29) and siCav-1 to disrupt the caveolae. Then the BMP-dependent Smad phosphorylation and Smad signaling activity were detected by Western blot and luciferase gene reporter assays before and after disruption of CCPs and caveolae. Figure 5A shows Western blot band images of phosphorylated and total Smad1/5/8 after the CCPs were disrupted by CPZ. The C2C12 cells were transfected with wild-type BMPR2 or mutants for 17 h, and CPZ was added to the medium to disrupt CCPs with or without BMP2 stimulation for 1 h. The normalized band intensities with or without disrupted CCPs are shown in Fig. 5B . After disruption of CCPs, Smad1/ Fig. 4 . Mutants decreased colocalization with caveolae composed of caveolin-1␣/␤ (P Ͻ 0.05) but increased colocalization in caveolae composed of caveolin-1␣ (P Ͻ 0.05) and clathrin-coated pits (CCPs; P Ͻ 0.05) on hPASMC membrane. A-C: overlay images of wild-type BMPR2-GFP (green stain) with caveolin-1␣/␤, caveolin-1␣, and adaptor protein 2 (AP-2, red stain). Scale bars 2 m. D-F: localization of wild-type BMPR2 and 3 mutants with caveolin-1␣/␤, caveolin-1␣, and AP-2 with and without BMP2 stimulation. Wild-type BMPR2 and mutants localized in cell domains enriched with caveolin-1␣ and -1␤. With BMP2 stimulation, some wild-type BMPR2 shifted from the region enriched with caveolin-1␤ to the region enriched with caveolin-1␣. More mutants colocalized with caveolin-1␣/␤ (P Ͻ 0.05) and caveolin-1␣ (P Ͻ 0.05) with BMP2 stimulation. There is no evidence that they shifted from caveolin-1␤ to -1␣. With AP-2, colocalization was 2-fold greater in mutants (P Ͻ 0.05) than in the wild-type receptor, and BMP2 stimulation did not change colocalization of the wild-type receptor and mutants.
5/8 phosphorylation of wild-type BMPR2 and R899X decreased, whereas that of D485G remained the same. Smad1/5/8 phosphorylation of N519K appeared to increase slightly.
In the luciferase gene reporter assays (Fig. 5, C and D) , the C2C12 cells were transfected with pSBE, pRL-Luc, and wildtype BMPR2 or mutants, and the cells were stimulated with BMP2 for 18 h or left unstimulated. To disrupt the CCPs, CPZ was added to the cells for 18 h, with or without transfection with a mutant of Eps15, EH29 plasmid, at the time of the receptor transfection. Similar results were obtained for Smad signaling activity after the CCPs were disrupted by CPZ (Fig.  5C ) and EH29 plasmid (Fig. 5D ). Similar to Smad phosphorylation, Smad signaling activity of the wild-type receptor also decreased, whereas the signaling activity of N519K was restored to a great degree. This result suggests that N519K may be trapped in the CCPs, so that when EH29 and CPZ disrupted the CCPs, the N519K mutant was released, and its signaling activity was restored.
Similar Western blot and luciferase gene reporter assay experiments were carried out with or without disruption of caveolae by nystatin and siCav-1 in C2C12 cells. The Western blot band images of phosphorylated and total Smad1/5/8 after the caveolae were disrupted by nystatin are shown in Fig. 6A . The normalized phosphorylated Smad1/5/8 band intensities with and without nystatin-disrupted caveolae (Fig. 6B) show that phosphorylated Smad1/5/8 of the wild-type receptor decreased after disruption of caveolae, while that of the D485G mutant increased and that of the other two mutants also decreased to some extent. The effect of nystatin and siCav-1 on downstream Smad signaling is shown in Fig. 6 , C and D. Similar to our results in cells treated with CPZ and EH29, the signaling activity of the wild-type receptor decreased significantly with disruption of the caveolae by nystatin and siCav-1. The signaling activity of D485G has been enhanced to a great degree in the same experimental conditions. The signaling activity of D485G recovered after disruption of the caveolae, illustrating that the kinase domain mutant D485G may be trapped in caveolae and that disruption of caveolae released the mutant and recovered the signaling activity of the mutant receptor.
DISCUSSION
In our Western blot (see Supplemental Fig. S1, A and B) and luciferase reporter gene (see Supplemental Fig. 1C ) assays, all three overexpressed mutants inhibit BMP-dependent Smad a Significantly different from wild-type BMPR2 (ϪCPZ/EH29).
b Significantly different from wild-type BMPR2 (ϩCPZ/ EH29).
c Significantly different from ϪCPZ/EH29 within group. P Ͻ 0.05 was considered statistically significant as determined by ANOVA followed by Tukey's test. phosphorylation and Smad signaling. With more mutant plasmid transfection (2.0 g), the Smad signal of the kinase domain mutant D485G was even lower than the endogenous Smad signal (mock sample, see Supplemental Fig. S5 ). These results show the dominant-negative effect of D485G and are consistent with previous observations that the D485G mutant lost almost all Smad signaling ability, even though it exhibited normal ligand-binding capability (18, 20) .
The ICS analysis results (Figs. 2 and 3) suggest that even though they reach the cell surface, the mutant receptors do not form highly aggregated clusters on the membrane, as wild-type receptors do. After BMP2 stimulation, the mutant receptors aggregate to some extent, but they are still highly dispersed on the cell membrane compared with unstimulated and stimulated wild-type receptors. The cytoplasmic tail mutants are slightly more responsive to BMP2 stimulation, consistent with their slightly elevated Smad phosphorylation and slightly higher Smad signaling activity. The ICCS analysis results (Fig. 4) suggest different distributions of wild-type receptors and mutants among membrane domains. BMP signaling was shown to be dependent on receptor localization with distinct membrane domains. These domains include caveolae and CCPs. Caveolae exist in two different structures on the plasma membrane: they form shallow or deep invaginations. These caveolae are composed of caveolin-1␣/␤ or -1␤. Receptor signaling is enhanced by shuttling of the BMP receptors on the plasma membrane within caveolae composed of caveolin-1␤ to caveolae composed of caveolin-1␣/␤ and CCPs (3, 24 -26) . Here, we show that the receptors not only are expressed on the cell membrane at different aggregation states, but also their colocalization with cell-specific domains was different from that of wild-type BMPR2. A small number of BMPR2 colocalize in caveolae composed of caveolin-1␤ only, while the mutants do not localize in these domains. Although caveolin-1␤ overexpression was shown to be inhibitory to BMP signaling, BMP stimulation of A431 cells led to the shuttling of BMP receptors from domains composed of the ␤-isoform to domains enriched with the ␣-isoform. At the same time, shuttling of BMP receptors significantly enhanced BMP signaling (24, 26) .
Structurally, BMPR2 is similar to other type II receptors of the TGF-␤ superfamily, such as T␤R-II, ActR-IIA, and ActR-IIB. However, BMPR2 has a long cytoplasmic tail that is not found in other type II receptors in mammals. The functions of the cytoplasmic tail of BMPR2 are not clear (24) . Compared with the wild-type receptor, distributions of the truncating mutation (R899X) and the single site mutation (N519K) on the cell surface are quite different, even though they are expressed at functionally high levels. They have lost the ability to form Fig. 6 . Disruption of caveolae decreased BMP signaling of wild-type BMPR2 but restored signaling of D485G with BMP2 stimulation in C2C12 cells. A: Western blot bands of phosphorylated Smad1/5/8 and total Smad1/5/8 of wild-type BMPR2 and mutants with or without BMP2 stimulation and with nystatin-disrupted caveolae. B: normalized band intensities of phosphorylated Smad1/5/8 with BMP2 stimulation with and without nystatin-disrupted caveolae (ϩnystatin and Ϫnystatin, respectively). C: normalized downstream Smad signaling activities of the wild-type receptor and mutants with BMP2 stimulation with and without nystatin-disrupted caveolae. Smad signaling of wildtype BMPR2 (P Ͻ 0.0001) and D485G (P Ͻ 0.01) was significantly different from that of untreated cells. D: normalized downstream Smad signaling activities of the wild-type receptor and mutants with BMP2 stimulation with and without caveolin-1 small interfering RNA (siCav-1) transfection (ϩsi-Cav-1 and ϪsiCav-1, respectively). Smad signaling of wild-type BMPR2 (P Ͻ 0.05) and D485G (P Ͻ 0.05) was significantly different from that of untreated cells. With nystatin and siCav-1 disrupting the caveolae, signaling of D485G increased significantly, which suggests that D485G may be trapped in the caveolae. Results are averages of 3 individual experiments.
a Significantly different from wild-type BMPR2 (Ϫnystatin/siCav-1).
b Significantly different from wild-type BMPR2 (ϩnystatin/siCav-1).
c Significantly different from Ϫnystatin/siCav-1 within group. P Ͻ 0.05 was considered statistically significant as determined by ANOVA followed by Tukey's test.
highly aggregated clusters. Thus the cytoplasmic tail may have a role in maintaining an aggregated distribution of the receptor in association with domains like the caveolae. The truncating mutations in the cytoplasmic tail found in some PAH patients might prevent normal function of BMPR2 in a similar manner. The mutation in the kinase domain (D485G) also seems to prevent aggregation of the receptor on the cell surface. The effect of this mutation is functionally more severe and suggests that other factors, in addition to the state of aggregation, contribute to the almost total loss of Smad phosphorylation and Smad signaling function.
The cysteine-substituted BMPR2 mutant C118W failed to be tracked to the cell membrane and, therefore, totally lost Smad signaling activity (21, 31) . Recently, it was found that C118W was mainly retained in the endoplasmic reticulum. Treatment of the cells with some chemical chaperones, such as thapsigargin, glycerol, or sodium 4-phenylbutyrate, greatly increase the membrane expression of C118W. The increased cell surface expression of C118W also enhanced BMP-dependent Smad1/5 phosphorylation (33) . In this study, disruption of caveolae and CCPs decreased the Smad phosphorylation and downstream Smad signaling response to BMP2 stimulation when BMPR2 was overexpressed. Recently, disruption of cells with CPZ or EH29 was shown to activate Smad phosphorylation (3). Therefore, the decrease in activation may be due to the overexpression of BMPR2 in these cells. In contrast, the mutants D485G and N519K recovered much of their Smad signaling activities after disruption of caveolae and CCPs, respectively, suggesting that their functions were inhibited because they were trapped in these domains. However, the R899X mutant did not show restoration after the disruption, similar to the wild-type receptor, and even showed decreased Smad phosphorylation and Smad signaling activity to some degree after disruption of caveolae and CCPs. Our ICS and ICCS results show that the three mutants have similar expression and aggregation on the cell membrane, as well as similar colocalization with cell domains, but they have different responses to BMP2 stimulation: R899X is more sensitive to BMP2 stimulation than D485G and N519K.
Taken together, the results presented here provide insight into the regulation of BMP signaling on the receptor level. Loss of ability to aggregate or colocalization in caveolae of the ␤-isoform prior to BMP stimulation appears to inhibit function but is probably not sufficient to completely abolish function. Trapping of the mutants in distinct cell domains, such as caveolae or CCPs, also greatly inhibits their BMP-dependent Smad phosphorylation and Smad signaling. It is possible that the BMP receptors in PAH patients also lack the ability to aggregate and localize on the cell membrane and are trapped in cell membrane domains, which contributes to inhibition or misdirection of BMP signaling. Finding means to enhance aggregation or redistribution of the BMP receptors may provide a way to slow or eliminate the progress of PAH.
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